Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
4D-110 · 1 trial · 1 indication
Frequency and severity of ocular and systemic AEs including clinically significant changes in ocular evaluations, systemic examinations and laboratory testing.
| Arm | Type | Description |
|---|---|---|
| 4D-110 Dose 1 | EXPERIMENTAL | 4D-110 IVT injection |
| 4D-110 Dose 2 | EXPERIMENTAL | 4D-110 IVT injection |
| 4D-110 Dose 3 | EXPERIMENTAL | 4D-110 IVT injection |
| Name | Type | Description |
|---|---|---|
| 4D-110 | BIOLOGICAL | 4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene. |
Key Inclusion Criteria: * Diagnosis of CHM defined as a pathogenic mutation in the CHM gene, confirmed by genetic testing * Both eyes must have ≥ 34 ETDRS letters (\~20/200) Key Exclusion Criteria: * Clinically significant, active ocular or peri-ocular infection or inflammation in the study eye *...
4D-110 is an investigational therapy being developed for the treatment of choroideremia, a rare inherited retinal disease that causes progressive vision loss. It is administered via intravitreal injection and is currently in Phase 1 clinical development.
4D-110 targets the CHM gene, which is associated with choroideremia. The therapy is designed to address the underlying genetic cause of the disease by delivering a functional copy of the CHM gene to retinal cells.
4D-110 is being developed by 4D Molecular Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol FDMT. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
4D-110 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is a dose escalation study in patients with choroideremia.
4D-110 is being evaluated in a Phase 1 clinical trial with the identifier NCT04483440. This is a dose escalation study of intravitreal 4D-110 in patients with choroideremia. The trial is active but not recruiting, with an enrollment of 13 participants in the United States.
4D-110 is a distinct investigational product developed by 4D Molecular Therapeutics. No alternative names for this drug have been reported in the available clinical trial information.